- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled - - Applications for IND and Breakthrough Status Filed…
Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll…
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"),…
LONDON, June 25, 2025 /PRNewswire/ -- The Longitude Prize on ALS, a £7.5 million global challenge prize, has launched to…
Innovate GBM Community Innovate GBM’s Community Members gather at the NASDAQ Closing Bell Ceremony—united in a mission to bridge the…
TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company…
RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile Ethics approval and Phase 1 clinical trial start…
OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased…
OXFORD, England and CHICAGO, Ill., June 24, 2025 /PRNewswire/ -- Today, Brainomix, a pioneer in stroke artificial intelligence (AI) imaging…
MACAU, June 23, 2025 /PRNewswire/ -- Brain science technology company PanBrain Tech Co., Ltd. drew widespread attention at the BEYOND…